Monitor the September 3, 2026 CLYM116 Phase 1 data readout, which is the next major catalyst. With cash runway through H2 2028, the company is well-funded to reach multiple Phase 2 data milestones. The EPS beat is a mechanical artifact of small numbers and should not be overinterpreted.
Price Chart
Executive Summary
Climb Bio reported Q2 2026 results with a net loss of $13.5M ($0.18 loss per share), beating consensus of $0.22 by 18%. The company ended the quarter with $239.2M in cash, bolstered by the April 2026 private placement, extending runway into H2 2028. Pipeline progress remains on track with multiple data readouts expected in Q4 2026 and a key CLYM116 Phase 1 data event on September 3, 2026.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and marketable securities were $239.2M as of June 30, 2026, up from $160.7M at December 31, 2025.
- Net loss for Q2 2026 was $13.5M ($0.18 per share), versus $8.7M ($0.13 per share) in Q2 2025.
- Consensus EPS estimate was -$0.22; actual -$0.18 represents an 18% beat.
- R&D expenses were $9.7M for Q2 2026 vs $6.6M in Q2 2025; G&A expenses were $5.6M vs $4.1M.
- CLYM116 Phase 1 healthy volunteer data to be presented at R&D Spotlight on September 3, 2026.
- Budoprutug programs in pMN, ITP, and SLE continue enrolling; data expected in Q4 2026.
- Private placement of ~$110M completed in April 2026; cash runway extended into second half of 2028.
Financial Impact
Cash increased $78.5M from December 2025 to $239.2M, extending runway past 2 years. EPS beat consensus by 18% on a small base, but pre-revenue biotech earnings are not a primary driver.
Risk Factors
- Clinical trial failures or delays in budoprutug or CLYM116 programs
- Dilution risk from future capital raises if cash needs increase
- No revenue or near-term commercialization prospects
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-336762 |
| Document: clym-20260806.htm | 0001193125-26-336762 |
| Document: 0001193125-26-336762-index-headers.html | 0001193125-26-336762 |
| Document: 0001193125-26-336762-index.html | 0001193125-26-336762 |
| Document: 0001193125-26-336762.txt | 0001193125-26-336762 |
| 8-K Data (Synthetic) | 0001193125-26-336762 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $8.81 $9.57 | ▲ +8.63% | ▲ +8.07% | $9.57 (+8.63%) |
Oct 23, 2026 4d ago | 8-K | $8.81 $9.57 | ▲ +8.63% | ▲ +8.07% | $9.57 (+8.63%) |
Oct 23, 2026 4d ago | Press Release | $8.81 $9.57 | ▲ +8.63% | ▲ +8.07% | $9.57 (+8.63%) |
Sep 22, 2026 5w ago | Institutional Cluster | $14.21 $12.52 | ▼ −11.89% | ▼ −11.17% | $9.57 (−32.65%) |
Sep 3, 2026 7w ago | 8-K | $14.59 $15.52 | ▲ +6.37% | ▲ +6.76% | $9.57 (−34.41%) |
Aug 14, 2026 10w ago | 8-K | $16.33 $17.44 | ▲ +6.80% | ▲ +7.27% | $9.57 (−41.40%) |
Aug 6, 2026 11w ago | 8-K | $14.00 $14.00 | · 0.00% | ▼ −0.61% | $9.57 (−31.64%) |
Jun 30, 2026 17w ago | 144 | $13.29 $12.90 | ▼ −2.93% | ▼ −2.80% | $9.57 (−27.99%) |
Jun 12, 2026 19w ago | 8-K | $11.49 $10.71 | ▲ +6.79% | ▲ +6.19% | $9.57 (+16.71%) |
Jun 12, 2026 19w ago | 424B5 | $11.49 $10.71 | ▲ +6.79% | ▲ +6.19% | $9.57 (+16.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers